ALT/AST results were different from those seen in clinical trials, where elevated ALT/AST levels at least three times the upper limit of the normal range were observed in 4.9–13.0% of patients with lung fibrosis treated with nintedanib compared with placebo (up to 3.6%), depending on the study [7, 8, 12, 13]. The gene discussed is GPT; the disease is pulmonary fibrosis.